fig2

Fulminant myocarditis and cardiogenic shock in rheumatological disease: a case report

Figure 2. Timeline of therapeutic strategy during the acute phase. Temporal sequence of primary therapeutic interventions administered to the patient during the acute phase of fulminant myocarditis and cardiogenic shock. Key treatments highlighted include mechanical circulatory support with ECMO (Extracorporeal Membrane Oxygenation) and Impella device(“EC-pella approach”) and empirical immunosuppressive therapy with high-dose methylprednisolone (14 mg/kg/day for 3 days and then tapered), plasmapheresis and IVIG (intravenous immunoglobulins).